Biotechnology

A German biotech's novel drug just won a key FDA designation, a strategic move that could redefine the limits of liver surgery and cancer treatment.

JATT III Acquisition Corp's $60M IPO isn't just another SPAC. It’s a calculated bet by a proven team on the future of AI in drug discovery. But does it signal a new era for biotech M&A?

A new FDA petition aims to slash drug development costs for copies of even the most complex medicines. Is this the key to global access or a threat to innovation?

Biopharma is quietly ditching animal-derived components for safer, more reliable alternatives. Nu-Tek BioSciences' push at BPI East signals a major shift.

The strategic acquisition combines engineered probiotics with CRISPR-based technology, creating a powerful new toolkit to revolutionize livestock health.

A landmark $1.5B+ deal for a Chinese drug marks a major global shift. Haisco's innovative partnership with a US venture is reshaping biotech collaboration.

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

As Mesoblast prepares its year-end webcast, investors weigh a stellar $115M Ryoncil launch against cash burn and the high-stakes progress of its next-gen therapies.

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

A new partnership between a top R&D center and a health sciences university aims to fuse AI with biomaterials, promising medical breakthroughs for Hong Kong.

With a new patent, a bold asset pivot, and a top-tier banking partner, PharmAla Biotech is signaling a new phase of commercial maturity in psychedelic medicine.

A proposed SXSW panel on longevity medicine forces a crucial question: Are we on the verge of restoring youth, or just drowning in promises? We look at the science.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

A new AI-designed eye drug gets clinical trial clearance, validating Matwings' iterative platform and signaling a major shift in biopharma R&D strategy.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

Venture builder Foresite Labs hires AstraZeneca's AI leader, Dr. Jorge Reis-Filho, in a strategic move that signals a new era for AI-driven company creation.

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.